Objectif The ENDA project, currently in operation since January 1994 and to which 11 laboratories in Western Europe participate, has four main endeavours: a) to develop and clinically validate serological assays for detection of antibodies against myorelaxants and major antibiotics, which still represent major problems. b) to clinically validate a cellular mediator release assay (leukotriene release), to be used particularly for the diagnosis of pseudo-allergy to apsirin and non-steroidal anti-inflammatory drugs, a major clinical problem c) to develop easier methods to detect lymphocyte stimulation to drugs, since that mechanism is to be found in all drug allergies and could become routinely applicable. d) lay the technical basis for wider epidemiological studies (pharmacovigilance) It is proposed to include in these studies in a first step 4 laboratories. Participants 1 and 2 ( Moscow, Russia- St. Petersburg, Russia) have wide immunological experience. Participant 1 can perform a,b and c parts of the programme; participant 2 will concentrate on aspects a and b. Participant 3 ( Cracow, Poland ) has a very imposing clinical experience in problem c) and could make a very useful contribution by validating a new mediator release test for aspirin allergy being developed within the frame of ENDA. Participant 4 (Tirana,Albania) could provide a serotheque from a population which has been very little exposed to drugs and to industrial products/chemicals in the past 50 years. This could provide useful epidemiological data , in order to asess the putative role of cosmetics and other chemical contacts in sensitization to drugs, a factor which is believe important in the rising incidence of sensitization to some drugs, such as myorelaxants. The problem of drug allergy is clinically important in Eastern Europe, particularly because there may be a lesser choice of alternative drugs available, when a patient has become allergic to a vital drug. A number of additional groups have and more will certainly manifest interest, but time did not allow to concretize their participation. In addition to projects and participants 1-4, the Coordinator therefore requests a travel fund enabling to foster the future participation of Eastern Europe scientists to ENDA workshops and activities. Programme(s) IC-PECO/COPERNICUS - Scientific and technological cooperation between the European Community and European non-member countries, 1992- Thème(s) 0201 - CEEC participation in BIOMEDICAL AND HEALTH RESEARCH programme Appel à propositions Data not available Régime de financement CSC - Cost-sharing contracts Coordinateur Universidad de Navarra Contribution de l’UE Aucune donnée Adresse 31080 Pamplona Espagne Voir sur la carte Coût total Aucune donnée Participants (3) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire Central Research Institute for Radiology Russie Contribution de l’UE Aucune donnée Adresse 70-4,Lenegradskaya 190000 St. Petersburg Voir sur la carte Coût total Aucune donnée Institute of Immunology - Russian Academy of Medical Sciences Russie Contribution de l’UE Aucune donnée Adresse 24-2,Kahirskoye Shosse Moskva Voir sur la carte Coût total Aucune donnée University School of Medicine in Krakow Pologne Contribution de l’UE Aucune donnée Adresse 8,Skawinska Street 31 066 Kraków Voir sur la carte Coût total Aucune donnée
